542 related articles for article (PubMed ID: 9809890)
21. Short-term comparative outcomes associated with the use of GP IIb/IIIa antagonists in patients undergoing coronary intervention.
Kimmelstiel C; Phang R; Rehman A; Rand W; Miele R; Rhofiry J; MacIsaac DA; Gouveia W; Denier D; Becker RC
J Thromb Thrombolysis; 2001 May; 11(3):203-9. PubMed ID: 11577258
[TBL] [Abstract][Full Text] [Related]
22. Minimizing bleeding complications of percutaneous coronary intervention and glycoprotein IIb-IIIa antiplatelet therapy.
Juran NB
Am Heart J; 1999 Oct; 138(4 Pt 2):297-306. PubMed ID: 10502235
[TBL] [Abstract][Full Text] [Related]
23. Platelet glycoprotein IIb/IIIa antagonists in percutaneous coronary revascularization.
Dangas G; Colombo A
Am Heart J; 1999 Jul; 138(1 Pt 2):S16-23. PubMed ID: 10385787
[TBL] [Abstract][Full Text] [Related]
24. A direct comparison of tirofiban and abciximab during percutaneous coronary revascularization and stent placement: rationale and design of the TARGET study.
Moliterno DJ; Topol EJ
Am Heart J; 2000 Nov; 140(5):722-6. PubMed ID: 11054616
[TBL] [Abstract][Full Text] [Related]
25. A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials.
Gurm HS; Tamhane U; Meier P; Grossman PM; Chetcuti S; Bates ER
Circ Cardiovasc Interv; 2009 Jun; 2(3):230-6. PubMed ID: 20031720
[TBL] [Abstract][Full Text] [Related]
26. Meta-analysis of clinical efficacy and bleeding risk with intravenous glycoprotein IIb/IIIa antagonists for percutaneous coronary intervention.
Labinaz M; Ho C; Banerjee S; Martin J; Chen S; Mensinkai S
Can J Cardiol; 2007 Oct; 23(12):963-70. PubMed ID: 17932572
[TBL] [Abstract][Full Text] [Related]
27. Spotlight on abciximab in patients with ischemic heart disease undergoing percutaneous coronary revascularization.
Ibbotson T; McGavin JK; Goa KL
Am J Cardiovasc Drugs; 2003; 3(5):381-6. PubMed ID: 14728074
[TBL] [Abstract][Full Text] [Related]
28. Current strategies with eptifibatide and other antiplatelet agents in percutaneous coronary intervention and acute coronary syndromes.
Jennings LK
Expert Opin Drug Metab Toxicol; 2005 Dec; 1(4):727-37. PubMed ID: 16863436
[TBL] [Abstract][Full Text] [Related]
29. PlA(1)/PlA(2) polymorphism does not influence response to Gp IIb-IIIa inhibitors in patients undergoing coronary angioplasty.
Verdoia M; Pergolini P; Camaro C; Restifo M; Rolla R; Schaffer A; Di Giovine G; Marino P; Bellomo G; Suryapranata H; De Luca G;
Blood Coagul Fibrinolysis; 2013 Jun; 24(4):411-8. PubMed ID: 23412353
[TBL] [Abstract][Full Text] [Related]
30. GP IIb/IIIa inhibitors in coronary artery disease management: what the latest trials tell us.
Chew DP; Moliterno DJ
Cleve Clin J Med; 2001 Dec; 68(12):1017-23. PubMed ID: 11765119
[TBL] [Abstract][Full Text] [Related]
31. Current knowledge of the platelet glycoprotein IIb/IIIa receptor antagonists for the treatment of coronary artery disease.
Berkowitz SD
Haemostasis; 2000; 30 Suppl 3():27-43. PubMed ID: 11182626
[TBL] [Abstract][Full Text] [Related]
32. IIb's are not IIb's.
Kereiakes DJ; Runyon JP; Broderick TM; Shimshak TM
Am J Cardiol; 2000 Apr; 85(8A):23C-31C. PubMed ID: 10793177
[TBL] [Abstract][Full Text] [Related]
33. Clinical trials of IIb/IIIa receptor blockers in patients undergoing angioplasty.
Mathew TP; Adgey AA
Semin Interv Cardiol; 1999 Jun; 4(2):67-75. PubMed ID: 10473875
[TBL] [Abstract][Full Text] [Related]
34. [GPIIb-IIIa inhibitors].
Nurden P
Transfus Clin Biol; 2001 Apr; 8(2):114-22. PubMed ID: 11386043
[TBL] [Abstract][Full Text] [Related]
35. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.
Ferguson JJ; Antman EM; Bates ER; Cohen M; Every NR; Harrington RA; Pepine CJ; Theroux P;
Am Heart J; 2003 Oct; 146(4):628-34. PubMed ID: 14564315
[TBL] [Abstract][Full Text] [Related]
36. Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials.
De Luca G; Navarese E; Marino P
Eur Heart J; 2009 Nov; 30(22):2705-13. PubMed ID: 19875386
[TBL] [Abstract][Full Text] [Related]
37. Glycoprotein IIb/IIIa receptor antagonists in the management of cardiovascular diseases.
Chong PH
Am J Health Syst Pharm; 1998 Nov; 55(22):2363-86. PubMed ID: 9825033
[TBL] [Abstract][Full Text] [Related]
38. Cost and effectiveness of glycoprotein IIb/IIIa-receptor inhibitors in patients with acute myocardial infarction undergoing percutaneous coronary intervention.
McCollam PL; Foster DA; Riesmeyer JS
Am J Health Syst Pharm; 2003 Jun; 60(12):1251-6. PubMed ID: 12845921
[TBL] [Abstract][Full Text] [Related]
39. Preferential benefit of platelet glycoprotein IIb/IIIa receptor blockade: specific considerations by device and disease state.
Kereiakes DJ
Am J Cardiol; 1998 Apr; 81(7A):49E-54E. PubMed ID: 9551595
[TBL] [Abstract][Full Text] [Related]
40. Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
Roe MT; Sapp SK; Lincoff AM
Cleve Clin J Med; 2000 Feb; 67(2):131-40. PubMed ID: 10680279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
